ECSP21067052A - SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR - Google Patents

SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR

Info

Publication number
ECSP21067052A
ECSP21067052A ECSENADI202167052A ECDI202167052A ECSP21067052A EC SP21067052 A ECSP21067052 A EC SP21067052A EC SENADI202167052 A ECSENADI202167052 A EC SENADI202167052A EC DI202167052 A ECDI202167052 A EC DI202167052A EC SP21067052 A ECSP21067052 A EC SP21067052A
Authority
EC
Ecuador
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
ECSENADI202167052A
Other languages
Spanish (es)
Inventor
Dominique Verstraete
michael Anne
Abhishek Singh
DYCKE Frederic VAN
Oliver Lenz
Jan Snoeys
Maria Jansens
Claire Balmain
Joris Vandenbossche
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of ECSP21067052A publication Critical patent/ECSP21067052A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.The present disclosure relates to solid oral dosage forms of a capsid assembly inhibitor for the treatment of hepatitis B virus infection.

ECSENADI202167052A 2019-03-13 2021-09-10 SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR ECSP21067052A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2019056348 2019-03-13
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
ECSP21067052A true ECSP21067052A (en) 2021-11-18

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202167052A ECSP21067052A (en) 2019-03-13 2021-09-10 SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR

Country Status (16)

Country Link
EP (1) EP3937928A1 (en)
JP (1) JP2022524819A (en)
KR (1) KR20210137484A (en)
CN (1) CN113557016A (en)
AU (1) AU2020235442A1 (en)
BR (1) BR112021017525A2 (en)
CA (1) CA3132095A1 (en)
CR (1) CR20210481A (en)
EC (1) ECSP21067052A (en)
IL (1) IL286209A (en)
JO (1) JOP20210250A1 (en)
MA (1) MA55280A (en)
MX (1) MX2021011030A (en)
PE (1) PE20212107A1 (en)
SG (1) SG11202109710QA (en)
WO (1) WO2020183020A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
SG11202007097QA (en) * 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202126620A (en) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11202007097QA (en) * 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
MA55280A (en) 2022-01-19
JP2022524819A (en) 2022-05-10
KR20210137484A (en) 2021-11-17
SG11202109710QA (en) 2021-10-28
CA3132095A1 (en) 2020-09-17
PE20212107A1 (en) 2021-11-04
BR112021017525A2 (en) 2021-11-23
EP3937928A1 (en) 2022-01-19
AU2020235442A1 (en) 2021-08-12
CR20210481A (en) 2021-10-25
CN113557016A (en) 2021-10-26
JOP20210250A1 (en) 2023-01-30
MX2021011030A (en) 2021-10-13
IL286209A (en) 2021-10-31
WO2020183020A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
CL2021000227A1 (en) Dosage regimen of the capsid assembly modulator. (application divisional 2254-2020)
CO2024006742A2 (en) Therapeutic compounds for HIV virus infection
CL2019000415A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of a hiv virus infection.
UY35362A (en) THERAPEUTIC COMPOUNDS
ECSP20020410A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME
UY37581A (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
CL2018001996A1 (en) Compositions and methods to modulate the expression of complement factor b (divisional application 2764-16)
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
UY37252A (en) COMPOUNDS FOR HEPATITIS B VIRUS INFECTION TREATMENT
MX2016003199A (en) AZAPIRIDONE COMPOUNDS AND USES OF THE SAME.
MX383447B (en) COMBINATION OF A CAPSID ASSEMBLY INHIBITOR AND PEGINTERFERON ALPHA-2A AND ITS USES FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTIONS.
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
CO2018000589A2 (en) Oxiesterols and pharmaceutical compositions containing them
CO2017007355A2 (en) Compounds derived from pyrazinecarbozamide and pyrazinecarboxylate for the treatment of hepatitis b virus infection
MX2017011655A (en) AZA-PIRIDONA COMPOUNDS AND USES OF THESE.
CL2020001358A1 (en) Modified brucella vaccine strain for the treatment of brucellosis
EA201890818A1 (en) COMBINED TREATMENT FOR HCV TREATMENT
BR112021017525A2 (en) Solid Capsid Assembly Modulator Formulation
MX2022008062A (en) USE OF THE FXR AGONIST FOR THE TREATMENT OF A HEPATITIS D VIRUS INFECTION.
UY37166A (en) NUCLEOSID ALKYLIN ANALOGS AS INHIBITORS OF HUMAN RINOVIRUS
MX2021006654A (en) Use of cocculus hirsutus extract for treating dengue.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
AR111017A1 (en) HEMISULFATE SALT OF A NUCLEOTID COMPOUND FOR THE TREATMENT OF HEPATITIS C VIRUS